Product development strategy

RNS Number:4725F
Amarin Corporation Plc
10 October 2007


                                      

       AMARIN ANNOUNCES INITIATION OF CARDIOVASCULAR DEVELOPMENT STRATEGY

     Capitalizing on Known Therapeutic Benefits of Unsaturated Fatty Acids
                           in Cardiovascular Disease


LONDON, United Kingdom, October 10, 2007 - Amarin Corporation plc (NASDAQ: AMRN)
today announced that it has initiated a cardiovascular development strategy to
capitalize on the known therapeutic benefits of unsaturated fatty acids in
cardiovascular disease. Amarin plans to utilize its extensive know-how and
experience in lipid science to develop a series of products targeting the
vascular system, endothelial dysfunction and vascular re-modeling.


Dr. Declan Doogan, Amarin's President of Research and Development commented
"Building on an extensive knowledge base in cardiovascular disease, we plan to
leverage our expertise in lipid science to create new therapies from our
existing family of compounds. We are fortunate to have the know-how, the
resources and the ability to draw on an extensive knowledge network in
cardiovascular disease."


Rick Stewart, Chief Executive Officer, commented "While neurology remains
Amarin's core focus, the new cardiovascular strategy capitalizes on existing
assets which already have an established safety and efficacy profile in Japan.
Consequently, this is a logical extension from Amarin's existing therapeutic
base for ultra-pure EPA and its derivatives. The expansion of Amarin's
therapeutic reach into diseases with a significantly greater prevalence than
neurological disease enhances our development portfolio mix and creates added
value from our lipid technology platform."


Amarin intends to commence a series of clinical trials with AMR 101 (97% pure
EPA) in dyslipidemia, the first of which will commence by the end of this year.
In addition, Amarin intends to commence investigation of new compounds from its
existing development portfolio for the treatment of metabolic syndrome and
dyslipidemia. Further information on dyslipidemia and metabolic syndrome is
included later in this press release.


Amarin believes that proof of concept with AMR 101 in cardiovascular disease can
be established relatively quickly and inexpensively as efficacy is measured by
well defined biochemical endpoints. This will enable rapid progress of effective
compounds into the final stages of development. These programs will be designed
and executed by an experienced and innovative drug development team.


In excess of two million patients in Japan have been prescribed ultra-pure EPA
for the treatment of high triglyceride levels (a component of dyslipidemia)
since its approval. The safety profile of ultra-pure EPA is very good,
especially in comparison to other triglyceride lowering agents such as fibrates,
statins and niacin.


It is estimated that total U.S. pharmaceutical sales in the cardiovascular
segment in 2006 were approximately $43.7 billion. The dyslipidemia market,
excluding statins, was estimated at approximately $2.2 billion in 2006,
representing a compound annual growth rate of 31% since 2002. The major driver
of this growth is believed to be an overall broadening of dyslipidemia treatment
beyond reduction in low density lipoprotein (LDL) cholesterol.


Endothelial dysfunction is a physiological dysfunction of normal biochemical
processes carried out by the endothelium, the cells that line the inner surface
of all blood vessels including arteries and veins (as well as the innermost
lining of the heart). Diseases associated with endothelial dysfunction are
amenable to vascular remodeling by unsaturated fatty acids, like AMR 101.
Endothelial dysfunction is associated with significant morbidity resulting from
diseases such as atherosclerosis, peripheral vascular disease, metabolic
syndrome (a component of which is dyslipidemia), ischaemic heart disease and
stroke.


AMR 101 is believed to impact on a number of biological factors in the body such
as anti-inflammatory mechanisms, cell membrane composition and plasticity,
triglyceride levels and regulation of glucose metabolism.


About Dyslipidemia

Dyslipidemia may be manifested by:

   * high levels of "bad" low-density lipoprotein (LDL) cholesterol,
   * high levels of triglycerides and
   * low levels of "good" high-density lipoprotein (HDL) cholesterol in the 
     blood.

About metabolic syndrome

Metabolic syndrome is characterized by a group of metabolic risk factors in one
person. They include:

    *insulin resistance or glucose intolerance
    *dyslipidemia
    *elevated blood pressure
    *obesity.

People with metabolic syndrome are at increased risk of coronary heart disease 
and other vascular disease (e.g., stroke and peripheral vascular disease) and 
type 2 diabetes. Metabolic syndrome has become increasingly common in the United
States. It is estimated that over 50 million Americans have metabolic syndrome.


About Amarin

Amarin is committed to improving the lives of patients suffering 
from central nervous system and cardiovascular diseases. Our goal is to be a 
leader in the research, development and commercialization of novel drugs that 
address unmet patient needs.

Amarin's CNS development pipeline includes two programs in Parkinson's disease, 
one in epilepsy and one in memory and cognition. Amarin is initiating a series 
of cardiovascular preclinical and clinical programs to capitalize on the known 
therapeutic benefits of unsaturated fatty acids in cardiovascular disease. 
Amarin also has a proprietary lipid-based technology platform for the targeted 
transport of molecules through the liver and/or to the brain that can be 
leveraged in a wide range of disease applications for its own product pipeline 
or with potential partners.Amarin has its primary stock market listing in the 
U.S. on NASDAQ("AMRN") and secondary listings in the U.K. and Ireland on AIM 
("AMRN") and IEX ("H2E"), respectively.

For press releases and other corporate information, visit the Amarin website at 
http://www.amarincorp.com. Information on our website does not form part of this
press release.

Contacts:

Amarin [phone]
Rick Stewart Chief Executive Officer
Alan Cooke President and Chief Financial Officer
[e-mail]

Investors:
Lippert/Heilshorn & Associates, Inc. [phone]
Anne Marie Fields
Bruce Voss [phone]

Media:
Powerscourt [phone]
Rory Godson
Sarah Daly


Disclosure Notice:

The information contained in this document is as of October 10, 2007. Amarin
assumes no obligation to update any forward-looking statements contained in this
document as a result of new information or future events or developments. This
document contains forward-looking statements about Amarin's financial condition,
results of operations, business prospects and products in research that involve
substantial risks and uncertainties. You can identify these statements by the
fact that they use words such as "will", "anticipate", "estimate", "expect",
"project", "forecast", "intend", "plan", "believe" and other words and terms of
similar meaning in connection with any discussion of future operating or
financial performance or events. Among the factors that could cause actual
results to differ materially from those described or projected herein are the
following: risks relating to the Company's ability to maintain its Nasdaq
listing (including the risk that the Company may not be able to achieve
compliance with the Nasdaq minimum bid price and/or other continued listing
criteria within the required timeframe or at all and the risk that the Company
may not be able to successfully appeal a Nasdaq delisting determination); the
success of Amarin's research and development activities, including its planned
clinical trials in cardiovascular disease; decisions by regulatory authorities
regarding whether and when to approve Amarin's drug applications, as well as
their decisions regarding labeling and other matters that could affect the
commercial potential of Amarin's products; the speed with which regulatory
authorizations, pricing approvals and product launches may be achieved; the
success with which developed products may be commercialized; competitive
developments affecting Amarin's products under development; the effect of
possible domestic and foreign legislation or regulatory action affecting, among
other things, pharmaceutical pricing and reimbursement, including under Medicaid
and Medicare in the United States, and involuntary approval of prescription
medicines for over-the-counter use; Amarin's ability to protect its patents and
other intellectual property; claims and concerns that may arise regarding the
safety or efficacy of Amarin's product candidates; governmental laws and
regulations affecting Amarin's operations, including those affecting taxation;
Amarin's ability to maintain sufficient cash and other liquid resources to meet
its operating requirements; general changes in International and US generally
accepted accounting principles; growth in costs and expenses; and the impact of
acquisitions, divestitures and other unusual items. A further list and
description of these risks, uncertainties and other matters can be found in
Amarin's Form 20-F for the fiscal year ended December 31, 2006, filed with the
SEC on March 5 2007, Amarin's statutory annual report for the year ended 31
December, 2006 furnished on a Form 6-K to the SEC on May 9, 2007 and in its
Reports of Foreign Issuer on Form 6-K furnished to the SEC.


                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
MSCBBBDGGXBGGRG